BlossomHill Therapeutics, Inc.: Quarterly report

BlossomHill Therapeutics advanced its oncology pipeline and completed an IPO to fund operations for at least 12 months.

Filed September 18, 2026 · period ended June 30, 2026

Mixed for the company

What the numbers say

Diluted EPS -$8.75 versus -$5.51; cash rose by $16.3M to $95.4M; diluted share count up 13% (dilution).

Compared with the same period a year earlier, from the figures BlossomHill Therapeutics, Inc. reported to the SEC.

What happened

The company generated no revenue from product sales and reported a net loss of $23,758 thousand for the second quarter of 2026.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to BlossomHill Therapeutics, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.